Patented technology regarding new and safe mechanism with the active substance PH3 for the indications of osteoporosis and diabetic vascular complications. More
Exclusive license for use of gabapentin in the above indications in EU, Canada, Australia, New Zealand. US Phase 3 trials of MR-gabapentin for menopause by PharmaNova’s US licensee (Depomed, Inc) will complete in 3Q 2009; Co-promotion in US is possible. More